SEATTLE NEW YORK CITY
Founded in 2003 in Seattle, Washington, Accelerator Corporation is a vehicle for capital-efficient investment in and management of emerging biotechnology opportunities. Formed by a syndicate of top-tier venture capital investors and supported by a consortium of world-class research institutions, Accelerator identifies, evaluates, finances, and manages the commercialization of technologies and assets sourced from a broad range of proprietary sources. Accelerator provides a unique set of start-up resources, the sum of which provide a complete business, scientific, and financial toolkit necessary for running an early-stage biotech company. Our array of resources nurtures our companies and their employees at all stages and in all facets of development, thereby providing them with the greatest chance of long-term success. Among these key resources are committed investment capital, experienced start-up management, world-class scientific expertise, and state-of-the-art laboratory and shared facilities.
Founded in 2003 in Seattle, Washington, Accelerator Corporation is a vehicle for capital-efficient investment in and management of emerging biotechnology opportunities. Formed by a syndicate of top-tier venture capital investors and supported by a consortium of world-class research institutions, Accelerator identifies, evaluates, finances, and manages the commercialization of technologies and assets sourced from a broad range of proprietary sources. Accelerator provides a unique set of start-up resources, the sum of which provide a complete business, scientific, and financial toolkit necessary for running an early-stage biotech company. Our array of resources nurture our companies and their employees at all stages and in all facets of development, thereby providing them with the greatest chance of long-term success. Among these key resources are committed investment capital, experienced start-up management, world-class scientific expertise, and state-of-the-art laboratory and shared facilities.

Accelerator provides this unprecedented collection of resources by establishing partnerships between top-tier investors, seasoned executive management, and several world-class research institutions, all of whom have experience in transforming a great idea into a viable commercial product. By lending their expertise to Accelerator’s portfolio companies, these industry leaders provide critical knowledge and resources that can help to streamline the development and commercialization of novel technologies and influence the rapidly evolving future of medicine and healthcare.

In addition to a proprietary pipeline of anchor investors and strategic stakeholders, Accelerator maintains access to leading global technologies and commercial opportunities developed at research institutions, universities and biotechnology companies around the world. This winning formula has allowed Accelerator to channel venture capital and unprecedented ground-up support to the most compelling investment opportunities.

 

In 2014, Accelerator expanded its scope of operations by opening a second operation in New York City. Accelerator’s startup development capabilities will thrive in New York City through partnerships that have been established between top-tier investors, seasoned executive management, and several world-class research institutions in New York City, all of whom have experience and capabilities that can be leveraged in helping to transform a great idea into a viable commercial product.

In selecting a location for expansion, Accelerator had three primary criteria: a critical mass of world-class research institutions; a relative lack of start-up capital for early-stage biotechnology opportunities; and the ability to seamlessly leverage our management team and capabilities to help companies that we fund.  It became obvious to all of us that New York City would serve as the ideal location to scale our operations, and we could not be more excited by the opportunity that we have before us to support the development of a vibrant life science ecosystem in New York City.  In addition, Accelerator will work in partnership with seven top-tier institutions, including Albert Einstein College of Medicine of Yeshiva University, Columbia University, Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, New York University, The Rockefeller University, and Weill Cornell Medical College.    Through this collaboration, we will have a unique opportunity to access some of the region’s most promising opportunities and collaborate with some of the world’s thought leaders in a variety of scientific disciplines that will be relevant to Accelerator.

  • All
  • Board of Directors
  • Senior Leadership
Bruce Carter

Dr. Bruce Carter

Independent Board Member

CLOSE X

Dr. Bruce Carter

Independent Board Member

Jessica Burback

Jessica Burback

Director, Operations

CLOSE X

Jessica Burback

Director, Operations

Jessica Burback joined Accelerator as its second full-time employee in September of 2003 as Assistant, Operations & Communications, became Senior Associate, Operations in 2006, Manager, Human Resources & Operations in 2012, and Director, Human Resources & Operations in 2013. At Accelerator, Ms. Burback oversees the firm’s operations, assists with the evaluation of portfolio investments, and coordinates human resources, marketing, communications and purchasing activities. Prior to joining Accelerator, Ms. Burback worked at Prolinx, Inc., a private, venture-backed company that developed, manufactured, and marketed chemistry based tools, applications, and systems to advance drug discovery. At Prolinx, Ms. Burback held various roles in operations and marketing. Ms. Burback received an MBA from Seattle University and BA in History from the University of Washington.

Alice Chen

Dr. Alice Chen

Vice President

CLOSE X

Dr. Alice Chen

Vice President

Dr. Alice Chen joined Accelerator in March of 2013 as a Principal, where she focuses on portfolio company operations, as well as sourcing and scientifically evaluating emerging biotechnology opportunities for Accelerator to invest in.  Before joining Accelerator, Dr. Chen served as a scientific and project management consultant for several biotechnology companies.  Prior to her consulting role, Dr. Chen was the Director of Technologies at Qwell Pharmaceuticals, a venture-backed biotechnology company developing novel, small-molecule drugs focused on cancer and inflammation.  Dr. Chen received her Ph.D. from Stanford University and her B.S. degree from U.C. Berkeley in Chemical Engineering, and was an Engineering Fellow at Merck & Co.  Her doctoral work focused on protein engineering and protein characterization. Dr. Chen is also Kauffman Fellow, Class 19.

Steve Gillis

Dr. Steven Gillis

Ph.D., Managing Director - ARCH Venture Partners

CLOSE X

Dr. Steven Gillis

Ph.D., Managing Director - ARCH Venture Partners

Steven Gillis is now a Managing Director at ARCH Venture Partners. Dr. Gillis was a founder and director of Corixa Corporation and served as the company’s Chief Executive Officer since inception and as its chairman since January of 1999. Corixa Corporation was acquired by GlaxoSmithKline in July of 2005. Prior to starting Corixa, Dr. Gillis was a founder and director of Immunex Corporation. From 1981 until his departure in 1994, Dr. Gillis served as Immunex’s Director of Research and Development, Chief Scientific Officer and Chief Executive Officer of Immunex’s Research and Development subsidiary. Dr. Gillis was interim Chief Executive officer of Immunex Corporation following its majority purchase by American Cyanamid Company. Dr. Gillis remained on the Board of Directors of Immunex until 1997. Immunex was acquired by Amgen in 2002. Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20). Dr. Gillis received his B.A. from Williams College in 1975 and his Ph.D. from Dartmouth College in 1978.

M. Johnston Erwin, Jr.

M. Johnston Erwin, Jr.

Vice President, Corporate Business Development - Eli Lilly and Company

CLOSE X

M. Johnston Erwin, Jr.

Vice President, Corporate Business Development - Eli Lilly and Company

Johnston serves as Vice President, Corporate Business Development at Eli Lilly and Company.  As a member of the Company’s Corporate Business Development operation, he works with the Lilly team and external partners to advance innovation by driving scientific breakthroughs through collaboration.  He works closely with regional investment funds and provides oversight and strategic guidance to these efforts.

Most recently, Johnston served as Global Brand Development Leader | Bone, Muscle and Joint Molecule Clinical Development.  He was named Global Brand Development Leader, Osteoporosis Products in 2003.  This was an expansion of the role he held since 2002 as Product Team Leader, Arzoxifene.  Johnston led the clinical team responsible for the global regulatory submissions of EVISTA and FORTEO.  Under his leadership, both brands were approved in more than 80 countries and reached blockbuster status with >$1 Billion in worldwide sales each.  Prior to 2002, he served as Director, Strategy and Business Development, Primary Care Product Group, for Lilly where he was responsible for Cardiovascular Disease, Women’s Health, and Infectious Disease therapeutic areas.  He also oversaw the product-CIALIS, another blockbuster.

Prior to joining Lilly in 1985, Johnston spent three years as a sales representative in Idaho and held leadership roles in Corporate Strategic Planning, Human Resources, Sales, Strategic Asset Management, and Corporate Business Development.

Johnston previously served on the boards of the Depressive and Manic-Depressive Association of Texas, the Young Philanthropists for Vision in Indiana, and the Cornea Research Foundation.  He currently serves on the executive boards of the Western Golf Association / Evans Scholars Foundation, Indiana State University (Board of Governors), Purdue University, and the Crooked Stick Golf Club in Carmel, Indiana.

Leroy Hood

Dr. Leroy Hood

M.D, Ph.D, President - Institute for Systems Biology

CLOSE X

Dr. Leroy Hood

M.D, Ph.D, President - Institute for Systems Biology

Dr. Hood is a pioneer in the systems approach to biology and medicine. His research has focused on the study of molecular immunology, biotechnology and genomics. Dr. Hood’s professional career began at Caltech, where he and his colleagues developed the DNA gene sequencer and synthesizer and the protein synthesizer and sequencer––four instruments that paved the way for the successful mapping of the human genome. A pillar in the biotechnology field, Dr. Hood has played a role in founding more than fourteen biotechnology companies, including Amgen, Applied Biosystems, Darwin, The Accelerator and Integrated Diagnostics. He is a member of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. Of the 6,000+ scientists world-wide who belong to one or more of these academies, Dr. Hood is one of only fifteen people accepted to all three. He is also a member of the American Philosophical Society and a Fellow of the American Academy of Arts and Sciences. His work has been widely published, and he has coauthored numerous textbooks in biochemistry, immunology, molecular biology and genetics, as well as a popular book on the human genome project, The Code of Codes. He is the recipient of numerous awards, including the Lasker Award for Studies of Immune Diversity, the Kyoto Prize in advanced technology, the Heinz Award for pioneering work in Systems Biology, and most recently, the coveted NAE 2011 Fritz J. and Delores H. Russ Prize for automating DNA sequencing that revolutionized biomedicine and forensic science. In addition to having received 17 honorary degrees from prestigious universities in the US and abroad, Dr. Hood has published more than 700 peer reviewed articles and currently holds 36 patents.

Thong Le

Thong Q. Le

Chief Executive Officer

CLOSE X

Thong Q. Le

Chief Executive Officer

Thong Q. Le serves as Chief Executive Officer (CEO) of Accelerator Corporation. With more than 20 years of experience in identifying, investing, managing, and successfully exiting numerous seed and early-stage investments, Mr. Le is positioned to grow and expand the Accelerator investment model. He currently serves as CEO and Director of Acylin Therapeutics and all Accelerator IV portfolio companies, which currently includes Lodo Therapeutics and Petra Pharma. He also serves as a director of AgTech Accelerator, an investment vehicle focused on the development of next-generation agriculture companies.

Prior to becoming CEO at Accelerator, Mr. Le served as a Managing Director at WRF Capital, the venture capital investment arm of Washington Research Foundation in Seattle, WA. During his 13-year tenure at WRF Capital, Mr. Le played a significant role in the early sourcing, financing, and development of numerous start-up companies, including Alder Biopharmaceuticals (NASDAQ: ALDR), Corus Pharma (acquired by Gilead Sciences), Halosource (LSE: HALO.L), Hyperion Therapeutics (Nasdaq: HPTX), Lumera (NasdaqNM: LMRA), Performant (acquired by Mercury Interactive), Pathway Medical Technologies (acquired by MEDRAD), and VLST (asset acquisition by major international pharmaceutical company). He also led WRF Capital’s investments in Accelerator, AnswerDash, ARZEDA, Cardeas Pharma, Resolve Therapeutics, and Uptake Medical, all companies where he was actively involved in establishing as a founding or early investor.

Prior to joining WRF Capital, Mr. Le was the founder, president and CEO of MiniMeals, Inc. and a consultant for Capital Management Consulting, Inc.  Earlier, he was at Raymond James & Associates, Singer & Xenos Investment Management Company and Capital Management Group LLC, a private investment firm specializing in biomedical ventures.

Mr. Le completed post-graduate studies at the Templeton College of Oxford University and earned a bachelor of arts cum laude in government from Harvard University. He currently serves on the executive boards of the Evergreen Venture Capital Association (EVCA), Life Science Washington, and the Washington Global Health Fund. He was previously named one of the region’s “40 Under 40” by the Puget Sound Business Journal.

Accelerator Corporation

Dr. Jonathan Mandelbaum

Associate

CLOSE X

Dr. Jonathan Mandelbaum

Associate

Jonathan Mandelbaum joined Accelerator in 2015 as an Associate, where he supports deal sourcing, due diligence and portfolio company operations. Prior to Accelerator, Jonathan was a scientist in the drug discovery unit at Millennium: The Takeda Oncology Company where he performed target identification and validation activities and collaborated with the business development group on evaluating external early-stage opportunities. He also performed his postdoctoral work at Millennium, helping to support target validation and predictive biomarker discovery work for a late-stage drug discovery program. Jonathan obtained his Ph.D. from Columbia University and received a B.Sc. in Biology from McGill University.

Joel Marcus

Joel Marcus

Chairman, Chief Executive Officer & Founder - Alexandria Real Estate Equities, Inc./Alexandria Venture Investments

CLOSE X

Joel Marcus

Chairman, Chief Executive Officer & Founder - Alexandria Real Estate Equities, Inc./Alexandria Venture Investments

Joel S. Marcus is the Chairman, Chief Executive Officer, and Founder of Alexandria Real Estate Equities, Inc. (NYSE:ARE), an urban office REIT uniquely focused on urban, world-class collaborative science and technology campuses in AAA innovation cluster locations. Mr. Marcus co-founded Alexandria in 1994 as a garage startup with a business plan and $19 million in seed capital and has led its growth into a publicly traded, investment-grade REIT. Alexandria has a total market capitalization of approximately $13 billion and significant market presence in key locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle Park. In 1996, Mr. Marcus also founded Alexandria Venture Investments, the company’s strategic venture capital arm, which he currently leads with a focus on novel, breakthrough discoveries in biopharmaceuticals, diagnostics, research tools, agtech, digital health, and technology. In 2011, Mr. Marcus co-founded the renowned Alexandria Summit, an invitation-only gathering of the world’s foremost visionaries from the biopharmaceutical, medical, academic, financial, philanthropic, advocacy, and government communities, to address the most critical global healthcare challenges. Prior to co-founding Alexandria, Mr. Marcus had an extensive legal career specializing in corporate finance and capital markets, venture capital, and mergers and acquisitions, with a unique expertise in the biopharmaceutical industry, and was one of the principal architects of the Kirin-Amgen EPO joint venture in 1984. He was also a practicing certified public accountant and tax manager with Arthur Young & Co., where he focused on the financing and taxation of REITs. Mr. Marcus was one of the original architects and co-founders of Accelerator Corporation and AgTech Accelerator, for which he serves on the board of directors. He also serves on the boards of Atara Biotherapeutics, Inc. (NASDAQ:ATRA), Biotechnology Innovation Organization (BIO), Foundation for the National Institutes of Health (FNIH), Friends of Cancer Research, Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), MedBlue Incubator, Inc., MeiraGTx Limited, Multiple Myeloma Research Foundation (MMRF), NYU Schack Institute of Real Estate, Partnership for New York City, and Yumanity Therapeutics, as well as on NAREIT’s 2017 Executive Board. Mr. Marcus is a recipient of the Ernst & Young Entrepreneur of the Year Award (Los Angeles – Real Estate). He was awarded his undergraduate and Juris Doctor degrees at the University of California, Los Angeles.

David McElligott

Dr. David McElligott

Chief Scientific Officer

CLOSE X

Dr. David McElligott

Chief Scientific Officer

Dr. David McElligott joined Accelerator in March of 2012 as its Chief ScientificOfficer. Previously, he served as the founding Chief Scientific Officer at Groove Biopharma, a microRNA therapeutics company, where he was responsible for leading the spin-out of the technology from Nanogen (now part of ELITech Group). Prior to founding Groove Biopharma, Dr. McElligott served as Senior Director of Biological Sciences at ICOS Corp. where he led numerous preclinical drug discovery projects in oncology, inflammation, and urology. Several of those projects led to successful IND filings and clinical development programs. Before joining ICOS in 1997, Dr. McElligott held academic appointments in the Department of Immunology at The Scripps Research Institute and The Salk Institute for Biological Sciences. Dr. McElligott received his Ph. D. and B.S degrees in Microbiology/Immunology from the University of Iowa. He also serves on the advisory boards of the NYU Innovation Venture Fund and Rockefeller University’s newly-established Robertson Therapeutic Development Fund.

Lindsay Rayle

Lindsay Rayle

Chief Financial Officer

CLOSE X

Lindsay Rayle

Chief Financial Officer

Lindsay Rayle joined Accelerator in January of 2004 as Director, Finance & Operations, became Controller and Vice President, Operations in 2009, and Chief Financial Officer in 2013. Ms. Rayle has more than 17 years of tax, accounting, finance, and operations management experience. She oversees all finance, accounting and day-to-day internal operations at Accelerator and Accelerator-backed portfolio companies. Prior to joining Accelerator, Ms. Rayle held a variety of finance and accounting positions at Prolinx, Inc., a private, venture-backed company that developed, manufactured, and marketed chemistry based tools, applications, and systems to advance drug discovery. Before joining Prolinx, Ms. Rayle worked as a Trust Associate for Plan Member Services Corporation. Ms. Rayle received an MBA from Seattle University and a BA in Business Administration with an emphasis in Accounting from the University of Puget Sound.

David Schubert

David M. Schubert

Chief Operating Officer

CLOSE X

David M. Schubert

Chief Operating Officer

David M. Schubert serves as Chief Operating Officer for Accelerator Corporation. From May of 2012- August of 2014, Mr. Schubert served as Executive Director of the Houston Area Translational Research Consortium (HATRC) at Rice University, a biotechnology-based non-for-profit organization that focused on filling the gap between R&D investment and translation of discovery to the clinic in the form of marketable products to treat diseases.   While at HATRC Mr. Schubert was a Venture Partner at Accelerator.

From 2005-May of 2012, Mr. Schubert served as the President and Chief Business Officer of Accelerator. Prior to Accelerator, in 2001 Mr. Schubert spun CellExSys out of Targeted Genetics Corporation  (where he led Business Development and Investor Relations from 1997-2001), and then successfully led the acquisition of CellExSys by Chromos Molecular Systems (Vancouver, BC).   Mr. Schubert began his career in 1993 at Baxter Healthcare Corporation where he served in various roles in strategic planning, sales and marketing in both Europe and the United States.

Mr. Schubert holds an MBA degree with concentrations in Marketing and Management from The Pennsylvania State University, an M.S. in Biology with a concentration in Immunology from Utah State University and a BS in Biology and a BA in Psychology from Eastern Nazarene College in Quincy, Massachusetts. Mr. Schubert serves as Chairman of the Board of Axonia Medical, and as member of the Board of Directors of The National Marrow Donor Program (NMDP).

James Sullivan 340x340

Dr. James P. Sullivan

Ph.D., Vice President, Pharmaceutical Discovery - AbbVie

CLOSE X

Dr. James P. Sullivan

Ph.D., Vice President, Pharmaceutical Discovery - AbbVie

James Sullivan, Ph.D., is Vice President, Discovery.  In this role, he is responsible for AbbVie’s research efforts in a variety of diseases including cancer, Alzheimer’s disease, hepatitis C, and a number of autoimmune disorders. He oversees a global network of scientists that includes AbbVie researchers at sites in the United States and Europe, and external research partners around the world.  Dr. Sullivan is a member of the R&D Leadership Team that has responsibility for the advancement of compounds in all stages of development, the Executive Licensing Steering Committee and the Scientific Governing Board for Abbvie.  He is also an executive sponsor for the AbbVie Women in Science organization. Jim joined Abbott in 1991 and has held various positions in the R&D organization. Jim has advanced multiple compounds into clinical development across multiple therapeutic areas including AbbVie’s recently launched combination product for HCV, the Bcl2 selective inhibitor, ABT-199, for oncology and a number of dual variable domain immunoglobulins (DVD-Igs) for rheumatoid arthritis and cancer. He has more than 130 scientific publications and is an inventor on 11 patents. He is an adjunct faculty member at Northwestern University of Chicago. He earned his bachelor’s degree and Ph.D. in biochemistry from Trinity College in Dublin, Ireland, and conducted post-doctoral research in neurobiology at Northwestern University.

Asish Xavier

Dr. Asish K. Xavier

Ph.D., Vice President, Venture Investments - Johnson & Johnson Development Corporation

CLOSE X

Dr. Asish K. Xavier

Ph.D., Vice President, Venture Investments - Johnson & Johnson Development Corporation

Asish Xavier, Vice President, Venture Investments, joined Johnson & Johnson Development Corporation in 2004.  Asish previously worked in business development at BioRexis Pharmaceutical Corporation which was acquired by Pfizer in 2007.  While at BioRexis, he assisted the company in raising a $30 million second round of financing.  Asish has worked in business development at Structural GenomiX, Inc., acquired by Eli Lilly in 2008, and was a project leader at Message Pharmaceuticals, Inc..

Asish received a Ph.D. from the University of Houston and a MBA from the Wharton School of the University of Pennsylvania, where he graduated with honors.  He received a Bachelor of Technology in Chemical Engineering from the Indian Institute of Technology, Kanpur, India.  Asish was a postdoctoral research Fellow in the Department of Chemistry at the Johns Hopkins University.

Bio_Tachi_Yamada

Dr. Tadataka Yamada

Independent Board Member

CLOSE X

Dr. Tadataka Yamada

Independent Board Member

Dr. Tadataka (Tachi) Yamada is a Venture Partner with Frazier Healthcare Partners.  Prior to joining Frazier he was Executive Vice-President, Chief Medical & Scientific Officer and a Board Member of Takeda Pharmaceuticals.  Dr. Yamada has served as President of the Bill & Melinda Gates Foundation Global Health Program.  In this position, he oversaw grants totaling more than $9 billion in programs directed at applying technologies to address major health challenges of the developing world including TB, HIV, malaria and other infectious diseases, malnutrition and maternal and child health.  He was formerly Chairman, Research and Development and a Member of the Board of Directors of GlaxoSmithKline and before that he was Chair of the Department of Internal Medicine and Physician-in-Chief at the University of Michigan Medical Center.

Dr. Yamada holds a bachelor’s degree in history from Stanford University and obtained his M.D. from New York University School of Medicine.  In recognition of his contributions to medicine and science he has been elected to membership in the National Academy of Medicine (US), the Academy of Medical Sciences (UK) and the National Academy of Medicine (Mexico) and he has received an honorary appointment as Knight Commander of the Most Excellent Order of the British Empire (KBE).  He is a Past-President of the Association of American Physicians and of the American Gastroenterological Association and hehas served as a member of the President’s Council of Advisors on Science and Technology and the Advisory Committee to the Director of the National Institutes of Health. He is currently Vice Chair of the Council of the National Academy of Medicine and serves on the Board of Directors of the Clinton Health Access Initiative.

  • All
  • Board of Directors
  • Senior Leadership
Jessica Burback

Jessica Burback

Director, Operations

Jessica Burback

CLOSE X

Jessica Burback

Director, Operations

Jessica Burback joined Accelerator as its second full-time employee in September of 2003 as Assistant, Operations & Communications, became Senior Associate, Operations in 2006, Manager, Human Resources & Operations in 2012, and Director, Human Resources & Operations in 2013. At Accelerator, Ms. Burback oversees the firm’s operations, assists with the evaluation of portfolio investments, and coordinates human resources, marketing, communications and purchasing activities. Prior to joining Accelerator, Ms. Burback worked at Prolinx, Inc., a private, venture-backed company that developed, manufactured, and marketed chemistry based tools, applications, and systems to advance drug discovery. At Prolinx, Ms. Burback held various roles in operations and marketing. Ms. Burback received an MBA from Seattle University and BA in History from the University of Washington.

Alice Chen

Dr. Alice Chen

Vice President

Alice Chen

CLOSE X

Dr. Alice Chen

Vice President

Dr. Alice Chen joined Accelerator in March of 2013 as a Principal, where she focuses on portfolio company operations, as well as sourcing and scientifically evaluating emerging biotechnology opportunities for Accelerator to invest in.  Before joining Accelerator, Dr. Chen served as a scientific and project management consultant for several biotechnology companies.  Prior to her consulting role, Dr. Chen was the Director of Technologies at Qwell Pharmaceuticals, a venture-backed biotechnology company developing novel, small-molecule drugs focused on cancer and inflammation.  Dr. Chen received her Ph.D. from Stanford University and her B.S. degree from U.C. Berkeley in Chemical Engineering, and was an Engineering Fellow at Merck & Co.  Her doctoral work focused on protein engineering and protein characterization. Dr. Chen is also Kauffman Fellow, Class 19.

Barbara Dalton

Dr. Barbara J. Dalton

Ph.D., Vice President Venture Capital, Worldwide Business Development Pfizer Inc

Barbara Dalton

CLOSE X

Dr. Barbara J. Dalton

Ph.D., Vice President Venture Capital, Worldwide Business Development Pfizer Inc

Dr. Dalton is responsible for Pfizer’s  Venture Investments, managing the current private equity portfolio and advising on equity transactions.  Dr Dalton was a founding member of EuclidSR Partners, a private venture capital firm.  She began her business career as a research scientist at SmithKline before moving to their venture capital subsidiary, S.R. One, Limited.   Barbara has managed diverse fund and company investments throughout the world.   She is an advisor to the Dean of the Penn State Eberly College of Science, where she received her undergraduate degree, and a member of The Penn State Research Foundation Board of Directors.  She leads the Healthcare Investing Group of the New York City Investment Fund and is a former member of the Board of Directors of the Alzheimer’s Disease Research Foundation, NY Biotech Association and the National Venture Capital Association.   Dr Dalton received her PhD in Immunology and Microbiology from The Medical College of Pennsylvania.

Steve Gillis

Dr. Steven Gillis

Ph.D., Managing Director - ARCH Venture Partners

Steve Gillis

CLOSE X

Dr. Steven Gillis

Ph.D., Managing Director - ARCH Venture Partners

Steven Gillis is now a Managing Director at ARCH Venture Partners. Dr. Gillis was a founder and director of Corixa Corporation and served as the company’s Chief Executive Officer since inception and as its chairman since January of 1999. Corixa Corporation was acquired by GlaxoSmithKline in July of 2005. Prior to starting Corixa, Dr. Gillis was a founder and director of Immunex Corporation. From 1981 until his departure in 1994, Dr. Gillis served as Immunex’s Director of Research and Development, Chief Scientific Officer and Chief Executive Officer of Immunex’s Research and Development subsidiary. Dr. Gillis was interim Chief Executive officer of Immunex Corporation following its majority purchase by American Cyanamid Company. Dr. Gillis remained on the Board of Directors of Immunex until 1997. Immunex was acquired by Amgen in 2002. Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20). Dr. Gillis received his B.A. from Williams College in 1975 and his Ph.D. from Dartmouth College in 1978.

M. Johnston Erwin, Jr.

M. Johnston Erwin, Jr.

Vice President, Corporate Business Development - Eli Lilly and Company

M. Johnston Erwin, Jr.

CLOSE X

M. Johnston Erwin, Jr.

Vice President, Corporate Business Development - Eli Lilly and Company

Johnston serves as Vice President, Corporate Business Development at Eli Lilly and Company.  As a member of the Company’s Corporate Business Development operation, he works with the Lilly team and external partners to advance innovation by driving scientific breakthroughs through collaboration.  He works closely with regional investment funds and provides oversight and strategic guidance to these efforts.

Most recently, Johnston served as Global Brand Development Leader | Bone, Muscle and Joint Molecule Clinical Development.  He was named Global Brand Development Leader, Osteoporosis Products in 2003.  This was an expansion of the role he held since 2002 as Product Team Leader, Arzoxifene.  Johnston led the clinical team responsible for the global regulatory submissions of EVISTA and FORTEO.  Under his leadership, both brands were approved in more than 80 countries and reached blockbuster status with >$1 Billion in worldwide sales each.  Prior to 2002, he served as Director, Strategy and Business Development, Primary Care Product Group, for Lilly where he was responsible for Cardiovascular Disease, Women’s Health, and Infectious Disease therapeutic areas.  He also oversaw the product-CIALIS, another blockbuster.

Prior to joining Lilly in 1985, Johnston spent three years as a sales representative in Idaho and held leadership roles in Corporate Strategic Planning, Human Resources, Sales, Strategic Asset Management, and Corporate Business Development.

Johnston previously served on the boards of the Depressive and Manic-Depressive Association of Texas, the Young Philanthropists for Vision in Indiana, and the Cornea Research Foundation.  He currently serves on the executive boards of the Western Golf Association / Evans Scholars Foundation, Indiana State University (Board of Governors), Purdue University, and the Crooked Stick Golf Club in Carmel, Indiana.

Leroy Hood

Dr. Leroy Hood

M.D, Ph.D, President - Institute for Systems Biology

Leroy Hood

CLOSE X

Dr. Leroy Hood

M.D, Ph.D, President - Institute for Systems Biology

Dr. Hood is a pioneer in the systems approach to biology and medicine. His research has focused on the study of molecular immunology, biotechnology and genomics. Dr. Hood’s professional career began at Caltech, where he and his colleagues developed the DNA gene sequencer and synthesizer and the protein synthesizer and sequencer––four instruments that paved the way for the successful mapping of the human genome. A pillar in the biotechnology field, Dr. Hood has played a role in founding more than fourteen biotechnology companies, including Amgen, Applied Biosystems, Darwin, The Accelerator and Integrated Diagnostics. He is a member of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. Of the 6,000+ scientists world-wide who belong to one or more of these academies, Dr. Hood is one of only fifteen people accepted to all three. He is also a member of the American Philosophical Society and a Fellow of the American Academy of Arts and Sciences. His work has been widely published, and he has coauthored numerous textbooks in biochemistry, immunology, molecular biology and genetics, as well as a popular book on the human genome project, The Code of Codes. He is the recipient of numerous awards, including the Lasker Award for Studies of Immune Diversity, the Kyoto Prize in advanced technology, the Heinz Award for pioneering work in Systems Biology, and most recently, the coveted NAE 2011 Fritz J. and Delores H. Russ Prize for automating DNA sequencing that revolutionized biomedicine and forensic science. In addition to having received 17 honorary degrees from prestigious universities in the US and abroad, Dr. Hood has published more than 700 peer reviewed articles and currently holds 36 patents.

Thong Le

Thong Q. Le

Chief Executive Officer

Thong Le

CLOSE X

Thong Q. Le

Chief Executive Officer

Thong Q. Le serves as Chief Executive Officer (CEO) of Accelerator Corporation. With more than 20 years of experience in identifying, investing, managing, and successfully exiting numerous seed and early-stage investments, Mr. Le is positioned to grow and expand the Accelerator investment model. He currently serves as CEO and Director of Acylin Therapeutics and all Accelerator IV portfolio companies, which currently includes Lodo Therapeutics and Petra Pharma. He also serves as a director of AgTech Accelerator, an investment vehicle focused on the development of next-generation agriculture companies.

Prior to becoming CEO at Accelerator, Mr. Le served as a Managing Director at WRF Capital, the venture capital investment arm of Washington Research Foundation in Seattle, WA. During his 13-year tenure at WRF Capital, Mr. Le played a significant role in the early sourcing, financing, and development of numerous start-up companies, including Alder Biopharmaceuticals (NASDAQ: ALDR), Corus Pharma (acquired by Gilead Sciences), Halosource (LSE: HALO.L), Hyperion Therapeutics (Nasdaq: HPTX), Lumera (NasdaqNM: LMRA), Performant (acquired by Mercury Interactive), Pathway Medical Technologies (acquired by MEDRAD), and VLST (asset acquisition by major international pharmaceutical company). He also led WRF Capital’s investments in Accelerator, AnswerDash, ARZEDA, Cardeas Pharma, Resolve Therapeutics, and Uptake Medical, all companies where he was actively involved in establishing as a founding or early investor.

Prior to joining WRF Capital, Mr. Le was the founder, president and CEO of MiniMeals, Inc. and a consultant for Capital Management Consulting, Inc.  Earlier, he was at Raymond James & Associates, Singer & Xenos Investment Management Company and Capital Management Group LLC, a private investment firm specializing in biomedical ventures.

Mr. Le completed post-graduate studies at the Templeton College of Oxford University and earned a bachelor of arts cum laude in government from Harvard University. He currently serves on the executive boards of the Evergreen Venture Capital Association (EVCA), Life Science Washington, and the Washington Global Health Fund. He was previously named one of the region’s “40 Under 40” by the Puget Sound Business Journal.

Accelerator Corporation

Dr. Jonathan Mandelbaum

Associate

Accelerator Corporation

CLOSE X

Dr. Jonathan Mandelbaum

Associate

Jonathan Mandelbaum joined Accelerator in 2015 as an Associate, where he supports deal sourcing, due diligence and portfolio company operations. Prior to Accelerator, Jonathan was a scientist in the drug discovery unit at Millennium: The Takeda Oncology Company where he performed target identification and validation activities and collaborated with the business development group on evaluating external early-stage opportunities. He also performed his postdoctoral work at Millennium, helping to support target validation and predictive biomarker discovery work for a late-stage drug discovery program. Jonathan obtained his Ph.D. from Columbia University and received a B.Sc. in Biology from McGill University.

Joel Marcus

Joel Marcus

Chairman, Chief Executive Officer & Founder - Alexandria Real Estate Equities, Inc./Alexandria Venture Investments

Joel Marcus

CLOSE X

Joel Marcus

Chairman, Chief Executive Officer & Founder - Alexandria Real Estate Equities, Inc./Alexandria Venture Investments

Joel S. Marcus is the Chairman, Chief Executive Officer, and Founder of Alexandria Real Estate Equities, Inc. (NYSE:ARE), an urban office REIT uniquely focused on urban, world-class collaborative science and technology campuses in AAA innovation cluster locations. Mr. Marcus co-founded Alexandria in 1994 as a garage startup with a business plan and $19 million in seed capital and has led its growth into a publicly traded, investment-grade REIT. Alexandria has a total market capitalization of approximately $13 billion and significant market presence in key locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle Park. In 1996, Mr. Marcus also founded Alexandria Venture Investments, the company’s strategic venture capital arm, which he currently leads with a focus on novel, breakthrough discoveries in biopharmaceuticals, diagnostics, research tools, agtech, digital health, and technology. In 2011, Mr. Marcus co-founded the renowned Alexandria Summit, an invitation-only gathering of the world’s foremost visionaries from the biopharmaceutical, medical, academic, financial, philanthropic, advocacy, and government communities, to address the most critical global healthcare challenges. Prior to co-founding Alexandria, Mr. Marcus had an extensive legal career specializing in corporate finance and capital markets, venture capital, and mergers and acquisitions, with a unique expertise in the biopharmaceutical industry, and was one of the principal architects of the Kirin-Amgen EPO joint venture in 1984. He was also a practicing certified public accountant and tax manager with Arthur Young & Co., where he focused on the financing and taxation of REITs. Mr. Marcus was one of the original architects and co-founders of Accelerator Corporation and AgTech Accelerator, for which he serves on the board of directors. He also serves on the boards of Atara Biotherapeutics, Inc. (NASDAQ:ATRA), Biotechnology Innovation Organization (BIO), Foundation for the National Institutes of Health (FNIH), Friends of Cancer Research, Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), MedBlue Incubator, Inc., MeiraGTx Limited, Multiple Myeloma Research Foundation (MMRF), NYU Schack Institute of Real Estate, Partnership for New York City, and Yumanity Therapeutics, as well as on NAREIT’s 2017 Executive Board. Mr. Marcus is a recipient of the Ernst & Young Entrepreneur of the Year Award (Los Angeles – Real Estate). He was awarded his undergraduate and Juris Doctor degrees at the University of California, Los Angeles.

David McElligott

Dr. David McElligott

Chief Scientific Officer

David McElligott

CLOSE X

Dr. David McElligott

Chief Scientific Officer

Dr. David McElligott joined Accelerator in March of 2012 as its Chief ScientificOfficer. Previously, he served as the founding Chief Scientific Officer at Groove Biopharma, a microRNA therapeutics company, where he was responsible for leading the spin-out of the technology from Nanogen (now part of ELITech Group). Prior to founding Groove Biopharma, Dr. McElligott served as Senior Director of Biological Sciences at ICOS Corp. where he led numerous preclinical drug discovery projects in oncology, inflammation, and urology. Several of those projects led to successful IND filings and clinical development programs. Before joining ICOS in 1997, Dr. McElligott held academic appointments in the Department of Immunology at The Scripps Research Institute and The Salk Institute for Biological Sciences. Dr. McElligott received his Ph. D. and B.S degrees in Microbiology/Immunology from the University of Iowa. He also serves on the advisory boards of the NYU Innovation Venture Fund and Rockefeller University’s newly-established Robertson Therapeutic Development Fund.

Lindsay Rayle

Lindsay Rayle

Chief Financial Officer

Lindsay Rayle

CLOSE X

Lindsay Rayle

Chief Financial Officer

Lindsay Rayle joined Accelerator in January of 2004 as Director, Finance & Operations, became Controller and Vice President, Operations in 2009, and Chief Financial Officer in 2013. Ms. Rayle has more than 17 years of tax, accounting, finance, and operations management experience. She oversees all finance, accounting and day-to-day internal operations at Accelerator and Accelerator-backed portfolio companies. Prior to joining Accelerator, Ms. Rayle held a variety of finance and accounting positions at Prolinx, Inc., a private, venture-backed company that developed, manufactured, and marketed chemistry based tools, applications, and systems to advance drug discovery. Before joining Prolinx, Ms. Rayle worked as a Trust Associate for Plan Member Services Corporation. Ms. Rayle received an MBA from Seattle University and a BA in Business Administration with an emphasis in Accounting from the University of Puget Sound.

David Schubert

David M. Schubert

Chief Operating Officer

David Schubert

CLOSE X

David M. Schubert

Chief Operating Officer

David M. Schubert serves as Chief Operating Officer for Accelerator Corporation. From May of 2012- August of 2014, Mr. Schubert served as Executive Director of the Houston Area Translational Research Consortium (HATRC) at Rice University, a biotechnology-based non-for-profit organization that focused on filling the gap between R&D investment and translation of discovery to the clinic in the form of marketable products to treat diseases.   While at HATRC Mr. Schubert was a Venture Partner at Accelerator.

From 2005-May of 2012, Mr. Schubert served as the President and Chief Business Officer of Accelerator. Prior to Accelerator, in 2001 Mr. Schubert spun CellExSys out of Targeted Genetics Corporation  (where he led Business Development and Investor Relations from 1997-2001), and then successfully led the acquisition of CellExSys by Chromos Molecular Systems (Vancouver, BC).   Mr. Schubert began his career in 1993 at Baxter Healthcare Corporation where he served in various roles in strategic planning, sales and marketing in both Europe and the United States.

Mr. Schubert holds an MBA degree with concentrations in Marketing and Management from The Pennsylvania State University, an M.S. in Biology with a concentration in Immunology from Utah State University and a BS in Biology and a BA in Psychology from Eastern Nazarene College in Quincy, Massachusetts. Mr. Schubert serves as Chairman of the Board of Axonia Medical, and as member of the Board of Directors of The National Marrow Donor Program (NMDP).

James Sullivan 340x340

Dr. James P. Sullivan

Ph.D., Vice President, Pharmaceutical Discovery - AbbVie

James Sullivan 340x340

CLOSE X

Dr. James P. Sullivan

Ph.D., Vice President, Pharmaceutical Discovery - AbbVie

James Sullivan, Ph.D., is Vice President, Discovery.  In this role, he is responsible for AbbVie’s research efforts in a variety of diseases including cancer, Alzheimer’s disease, hepatitis C, and a number of autoimmune disorders. He oversees a global network of scientists that includes AbbVie researchers at sites in the United States and Europe, and external research partners around the world.  Dr. Sullivan is a member of the R&D Leadership Team that has responsibility for the advancement of compounds in all stages of development, the Executive Licensing Steering Committee and the Scientific Governing Board for Abbvie.  He is also an executive sponsor for the AbbVie Women in Science organization. Jim joined Abbott in 1991 and has held various positions in the R&D organization. Jim has advanced multiple compounds into clinical development across multiple therapeutic areas including AbbVie’s recently launched combination product for HCV, the Bcl2 selective inhibitor, ABT-199, for oncology and a number of dual variable domain immunoglobulins (DVD-Igs) for rheumatoid arthritis and cancer. He has more than 130 scientific publications and is an inventor on 11 patents. He is an adjunct faculty member at Northwestern University of Chicago. He earned his bachelor’s degree and Ph.D. in biochemistry from Trinity College in Dublin, Ireland, and conducted post-doctoral research in neurobiology at Northwestern University.

Misti Ushio

Dr. Misti Ushio

Ph.D., Managing Director - Harris & Harris Group, Inc.

Misti Ushio

CLOSE X

Dr. Misti Ushio

Ph.D., Managing Director - Harris & Harris Group, Inc.

Misti Ushio is a Managing Director at Harris & Harris Group. Prior to joining Harris & Harris Group in 2007, Ms. Ushio worked at Merck & Co. for over 10 years in the BioProcess Research & Development group which focused on vaccines and biologics development, and was a Technology Licensing Officer at Columbia University.

Ms. Ushio currently serves on the board of AgBiome, LLC, Senova Systems, Inc., SynGlyco, Inc., ProMuc, Inc. and OpGen, Inc.  Her past investments include BioVex, Inc. (acquired by Amgen).

Ms. Ushio also serves on the board of the FastForward Accelerator at Johns Hopkins University and is on the Executive Oversight Committee for the Columbia University Coulter Foundation Grant.

She was graduated from Johns Hopkins University (B.S., Chemical Engineering), Lehigh University (M.S., Chemical Engineering) and University College London (Ph.D., Biochemical Engineering).

Asish Xavier

Dr. Asish K. Xavier

Ph.D., Vice President, Venture Investments - Johnson & Johnson Development Corporation

Asish Xavier

CLOSE X

Dr. Asish K. Xavier

Ph.D., Vice President, Venture Investments - Johnson & Johnson Development Corporation

Asish Xavier, Vice President, Venture Investments, joined Johnson & Johnson Development Corporation in 2004.  Asish previously worked in business development at BioRexis Pharmaceutical Corporation which was acquired by Pfizer in 2007.  While at BioRexis, he assisted the company in raising a $30 million second round of financing.  Asish has worked in business development at Structural GenomiX, Inc., acquired by Eli Lilly in 2008, and was a project leader at Message Pharmaceuticals, Inc..

Asish received a Ph.D. from the University of Houston and a MBA from the Wharton School of the University of Pennsylvania, where he graduated with honors.  He received a Bachelor of Technology in Chemical Engineering from the Indian Institute of Technology, Kanpur, India.  Asish was a postdoctoral research Fellow in the Department of Chemistry at the Johns Hopkins University.

Bio_Tachi_Yamada

Dr. Tadataka Yamada

Independent Board Member

Bio_Tachi_Yamada

CLOSE X

Dr. Tadataka Yamada

Independent Board Member

Dr. Tadataka (Tachi) Yamada is a Venture Partner with Frazier Healthcare Partners.  Prior to joining Frazier he was Executive Vice-President, Chief Medical & Scientific Officer and a Board Member of Takeda Pharmaceuticals.  Dr. Yamada has served as President of the Bill & Melinda Gates Foundation Global Health Program.  In this position, he oversaw grants totaling more than $9 billion in programs directed at applying technologies to address major health challenges of the developing world including TB, HIV, malaria and other infectious diseases, malnutrition and maternal and child health.  He was formerly Chairman, Research and Development and a Member of the Board of Directors of GlaxoSmithKline and before that he was Chair of the Department of Internal Medicine and Physician-in-Chief at the University of Michigan Medical Center.

Dr. Yamada holds a bachelor’s degree in history from Stanford University and obtained his M.D. from New York University School of Medicine.  In recognition of his contributions to medicine and science he has been elected to membership in the National Academy of Medicine (US), the Academy of Medical Sciences (UK) and the National Academy of Medicine (Mexico) and he has received an honorary appointment as Knight Commander of the Most Excellent Order of the British Empire (KBE).  He is a Past-President of the Association of American Physicians and of the American Gastroenterological Association and hehas served as a member of the President’s Council of Advisors on Science and Technology and the Advisory Committee to the Director of the National Institutes of Health. He is currently Vice Chair of the Council of the National Academy of Medicine and serves on the Board of Directors of the Clinton Health Access Initiative.

Benaroya Research Institute at Virginia Mason
Bloodworks Northwest
CoMotion at the University of Washington
Fred Hutchinson Cancer Research Center
Infectious Disease Research Institute (IDRI)
Institute for Systems Biology
Oregon Health & Science University
Pacific Northwest Diabetes Research Institute
Seattle BioMed
Seattle Children’s Research Institute
Washington State University
Albert Einstein College of Medicine, Inc.
Weill Cornell Medical College
The Rockefeller University
New York University
Memorial Sloan Kettering Cancer Center
Icahn School of Medicine at Mount Sinai
Columbia University